Alex Sparreboom

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

Alex Sparreboom, Judith van Asperen, Ulrich Mayer et al. · Proceedings of the National Academy of Sciences · 1997 · 877 citations · Full text

Active Epithelial Excretion, Gastrointestinal Pharmacology, Immunology +16

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

Ron H.J. Mathijssen, R J van Alphen, Jaco J. Verweij et al. · PubMed · 2001 · 752 citations

Cpt-11 Belongs, Chemoprevention Strategy, Pharmacotherapy +18

Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)

Alex Sparreboom, Charity D. Scripture, Vuong Trieu et al. · Clinical Cancer Research · 2005 · 492 citations · Full text

Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma

Qin Ryan, Donna Headlee, Milin Acharya et al. · Journal of Clinical Oncology · 2005 · 406 citations · Full text

Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity

Kelly K. Filipski, Ron H.J. Mathijssen, Torben Stamm Mikkelsen et al. · Clinical Pharmacology & Therapeutics · 2009 · 393 citations · Full text